Latest news with #IgM
Time of India
a day ago
- Health
- Time of India
Dedicated wards, test kits ready: Patna hospitals gear up to tackle dengue rise
1 2 3 4 Patna: With the district recording over twice the number of dengue cases till June this year as compared to the same period in 2024, hospitals have been directed to create dedicated wards and take other measures to prepare for a potential increase in the cases and other vector-borne diseases, as monsoon progresses. Patna district recorded 48 dengue cases by June 30, compared to around 20 during the same period the previous year. The district authorities anticipate that the number of cases will likely increase this year. Patna civil surgeon Dr Abinash Kumar Singh said that of the 48 dengue patients, 26 tested positive at private hospitals. "Preparation has already started for the prevention, testing and treatment of dengue. Around 10,000 combo kits (to detect both dengue virus NS1 antigen and IgG/IgM antibodies) have been procured, and will be given to the govt health facilities in the district. The hospitals have been asked to keep all required medicines, testing kits and mosquito nets ready for dengue patients," he said. The civil surgeon has directed the medical officers of the primary health centres to create two-bed dengue wards, the subdivisional hospitals to arrange for five-bed wards and govt hospitals to keep 10-bed wards ready. Nalanda Medical College and Hospital (NMCH)-Patna has been designated as the nodal centre for dengue in Patna, where a dedicated ward with 80 beds will be arranged. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo "At Patna Medical College Hospital, a 10-bed intensive care unit (ICU) will be created for dengue patients. The number of beds in dengue wards will be increased in hospitals as per requirement. Additionally, we have around 20 blood banks, including 14 private ones. The blood bank at Paras HMRI has the equipment to separate platelets," the civil surgeon told this newspaper. A health official said the dengue cases, however, peak around Sept-Oct. Around 250 dengue cases were being reported per day during peak time in Oct last year, he added. Patna district magistrate (DM) Thiyagarajan SM said all municipal officials have been asked to ensure preventive and cautionary measures to control dengue. He emphasised the need for vigilance during the rainy season, even though there was no current outbreak of dengue. The DM instructed the civil surgeon to keep rapid response teams active at all primary, urban primary and community health centres, besides referral hospitals. "Activities like intensive spraying of anti-larvae chemicals, house-to-house surveys, source reduction and awareness campaigns, including at schools, are being done. Large-scale promotion of 'Dos and Don'ts' is crucial," Thiyagarajan said, asking the municipal bodies to conduct fogging and ensure waterlogging is prevented. Active surveillance around confirmed dengue cases should be conducted to identify new patients, he told them. The DM directed all schools and colleges to follow the health advisories. "Students should be encouraged to wear clothes, covering most of their body. Educational institutions must maintain high standards of cleanliness and regularly spray anti-larvae chemicals (temephos) in drains," he said. Get the latest lifestyle updates on Times of India, along with Doctor's Day 2025 , messages and quotes!
Time of India
a day ago
- Health
- Time of India
With dengue cases doubling this yr from last, Patna hospitals gear up with dedicated wards
1 2 3 Patna: With the district recording over twice the number of dengue cases till June this year as compared to the same period in 2024, hospitals have been directed to create dedicated wards and take other measures to prepare for a potential increase in the cases and other vector-borne diseases, as monsoon progresses. Patna district recorded 48 dengue cases by June 30, compared to around 20 during the same period the previous year. The district authorities anticipate that the number of cases will likely increase this year. Patna civil surgeon Dr Abinash Kumar Singh said that of the 48 dengue patients, 26 tested positive at private hospitals. "Preparation has already started for the prevention, testing and treatment of dengue. Around 10,000 combo kits (to detect both dengue virus NS1 antigen and IgG/IgM antibodies) have been procured, and will be given to the govt health facilities in the district. The hospitals have been asked to keep all required medicines, testing kits and mosquito nets ready for dengue patients," he said. The civil surgeon has directed the medical officers of the primary health centres to create two-bed dengue wards, the subdivisional hospitals to arrange for five-bed wards and govt hospitals to keep 10-bed wards ready. Nalanda Medical College and Hospital (NMCH)-Patna has been designated as the nodal centre for dengue in Patna, where a dedicated ward with 80 beds will be arranged. "At Patna Medical College Hospital, a 10-bed intensive care unit (ICU) will be created for dengue patients. The number of beds in dengue wards will be increased in hospitals as per requirement. Additionally, we have around 20 blood banks, including 14 private ones. The blood bank at Paras HMRI has the equipment to separate platelets," the civil surgeon told this newspaper. Patna district magistrate (DM) Thiyagarajan SM said all municipal officials have been asked to ensure preventive and cautionary measures to control dengue. He emphasised the need for vigilance during the rainy season, even though there was no current outbreak of dengue. The DM instructed the civil surgeon to keep rapid response teams active at all primary, urban primary and community health centres, besides referral hospitals. "Activities like intensive spraying of anti-larvae chemicals, house-to-house surveys, source reduction and awareness campaigns, including at schools, are being done. Large-scale promotion of 'Dos and Don'ts' is crucial," Thiyagarajan said, asking the municipal bodies to conduct fogging and ensure waterlogging is prevented. Active surveillance around confirmed dengue cases should be conducted to identify new patients, he told them. The DM directed all schools and colleges to follow the health advisories. "Students should be encouraged to wear clothes, covering most of their body. Educational institutions must maintain high standards of cleanliness and regularly spray anti-larvae chemicals (temephos) in drains," he said. Get the latest lifestyle updates on Times of India, along with Doctor's Day 2025 , messages and quotes!
Time of India
a day ago
- Health
- Time of India
With dedicated dengue wards & testing kits, Patna dist hospitals all set to tackle dengue
1 2 Patna: Hospitals in Patna have been directed to create dedicated wards and take other measures to prepare for a potential increase in dengue fever cases and other vector-borne diseases, as the monsoon season progresses. Patna district recorded 48 dengue cases by June 30, compared to around 20 during the same period the previous year. The district authorities anticipate that the number of cases will likely increase this year. Patna civil surgeon Dr Abinash Kumar Singh said that of the 48 dengue patients, 26 tested positive at private hospitals. "Preparation has already started for the prevention, testing and treatment of dengue. Around 10,000 combo kits (to detect both dengue virus NS1 antigen and IgG/IgM antibodies) have been procured, and will be given to the govt health facilities in the district. The hospitals have been asked to keep all required medicines, testing kits and mosquito nets ready for dengue patients," he said. The civil surgeon has directed the medical officers of the primary health centres to create two-bed dengue wards, the subdivisional hospitals to arrange for five-bed wards and govt hospitals to keep 10-bed wards ready. Nalanda Medical College and Hospital (NMCH)-Patna has been designated as the nodal centre for dengue in Patna, where a dedicated ward with 80 beds will be arranged. "At Patna Medical College Hospital, a 10-bed intensive care unit (ICU) will be created for dengue patients. The number of beds in dengue wards will be increased in hospitals as per requirement. Additionally, we have around 20 blood banks, including 14 private ones. The blood bank at Paras HMRI has the equipment to separate platelets," the civil surgeon told this newspaper. Patna district magistrate (DM) Thiyagarajan SM said all municipal officials have been asked to ensure preventive and cautionary measures to control dengue. He emphasised the need for vigilance during the rainy season, even though there was no current outbreak of dengue. The DM instructed the civil surgeon to keep rapid response teams active at all primary, urban primary and community health centres, besides referral hospitals. "Activities like intensive spraying of anti-larvae chemicals, house-to-house surveys, source reduction and awareness campaigns, including at schools, are being done. Large-scale promotion of 'Dos and Don'ts' is crucial," Thiyagarajan said, asking the municipal bodies to conduct fogging and ensure waterlogging is prevented. Active surveillance around confirmed dengue cases should be conducted to identify new patients, he told them. The DM directed all schools and colleges to follow the health advisories. "Students should be encouraged to wear clothes, covering most of their body. Educational institutions must maintain high standards of cleanliness and regularly spray anti-larvae chemicals (temephos) in drains," he said. Get the latest lifestyle updates on Times of India, along with Doctor's Day 2025 , messages and quotes!
Yahoo
2 days ago
- Business
- Yahoo
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Dosing Plan to Initiate Clinical Studies in at Least Two Autoimmune Diseases in the Second Half of This Year Aurinia to Host Conference Call Today, June 30, at 8:30 a.m. ET ROCKVILLE, Md. & EDMONTON, Alberta, June 30, 2025--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). The study investigated aritinercept doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg and 300 mg and placebo, administered by subcutaneous injection, in 61 healthy subjects. Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade ≥3 adverse events, there were no treatment‑related serious adverse events (SAEs) and there were no discontinuations due to treatment-related adverse events. Adverse events that occurred in more than one subject included injection site reactions (24% aritinercept, 13% placebo), headache (11% aritinercept, 7% placebo), upper respiratory tract infection (7% aritinercept, 0% placebo) and back pain (4% aritinercept, 0% placebo). All injection site reactions were Grade 1. Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins (antibodies). Specifically, mean reductions from baseline to Day 28 of up to 48%, 55% and 20% were observed for immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG), respectively. "Dual inhibition of BAFF and APRIL to modulate B cells, including plasma cells, holds great promise in the treatment of a wide range of autoimmune immune diseases where these cells produce disease-causing autoantibodies," said Dr. Greg Keenan, Chief Medical Officer of Aurinia. "Based on today's positive results, which indicate robust and long‑lasting pharmacodynamic effects supportive of once-monthly dosing, we plan to initiate clinical studies of aritinercept in at least two autoimmune diseases in the second half of this year." Webcast & Conference Call Details A webcast and conference call will be hosted today, June 30, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA‑approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Forward-Looking Statements This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with the development of aritinercept and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia's most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) website at or the U.S. Securities and Exchange Commission's Electronic Document Gathering and Retrieval System (EDGAR) website at and on Aurinia's website at View source version on Contacts General Investor Inquiries ir@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
3 days ago
- Business
- Business Wire
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). The study investigated aritinercept doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg and 300 mg and placebo, administered by subcutaneous injection, in 61 healthy subjects. Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade ≥3 adverse events, there were no treatment‑related serious adverse events (SAEs) and there were no discontinuations due to treatment-related adverse events. Adverse events that occurred in more than one subject included injection site reactions (24% aritinercept, 13% placebo), headache (11% aritinercept, 7% placebo), upper respiratory tract infection (7% aritinercept, 0% placebo) and back pain (4% aritinercept, 0% placebo). All injection site reactions were Grade 1. Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins (antibodies). Specifically, mean reductions from baseline to Day 28 of up to 48%, 55% and 20% were observed for immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG), respectively. 'Dual inhibition of BAFF and APRIL to modulate B cells, including plasma cells, holds great promise in the treatment of a wide range of autoimmune immune diseases where these cells produce disease-causing autoantibodies,' said Dr. Greg Keenan, Chief Medical Officer of Aurinia. 'Based on today's positive results, which indicate robust and long‑lasting pharmacodynamic effects supportive of once-monthly dosing, we plan to initiate clinical studies of aritinercept in at least two autoimmune diseases in the second half of this year.' Webcast & Conference Call Details A webcast and conference call will be hosted today, June 30, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA‑approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Forward-Looking Statements This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with the development of aritinercept and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia's most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) website at or the U.S. Securities and Exchange Commission's Electronic Document Gathering and Retrieval System (EDGAR) website at and on Aurinia's website at
